The size of this cohort enabled us to elucidate rarer but significant molecular signatures, including 21q loss in glioblastoma as well as EGFR amplification and chromosome 22q loss in IDH1/2-mutant astrocytoma. This evidence concerns the gene EGFR and astrocytoma (excluding glioblastoma).